Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO): Eastern Mediterranean Bone Marrow Transplantation (EMBMT) group survey

Hematology/ Oncology and Stem Cell Therapy

Volumn 6, Issue 1, 2013, Pages 14-19

  Rasheed, Walid ^a   Ghavamzadeh, Ardeshir ^b   Hamladji, Rosemarie ^c   Othman, Tarek Ben ^d   Alseraihy, Amal ^a   Abdel Rahman, Fawzi ^e   Elhaddad, Alaa ^f   Alabdulaaly, Abdulaziz ^g   Dennison, David ^h   Ibrahim, Ahmad ⁱ   Bazarbachi, Ali ^j   Bekadja, Mohamed Amine ^k   Mohamed, Said Yousuf ^a   Adil, Salman Naseem ^l   Ahmed, Parvez ^m   Benchekroun, Said ⁿ   Ramzi, Mani ^o   Jarrar, Mohammad ^p   Alimoghaddam, Kamran ^b   Hussain, Fazal ^a   Hamidieh, Amir ^b   Aljurf, Mahmoud ^a   more..

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Centre Pierre et Marie Curie   (Algeria)

^d CENTRE NATIONAL DE GREFFE DE MOELLE OSSEUSE   (Tunisia)

^e KING HUSSEIN CANCER CENTER   (Jordan)

^f CAIRO UNIVERSITY   (Egypt)

^g Prince Sultan Military College of Health Science   (Saudi Arabia)

^h SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

ⁱ MAKASSED GENERAL HOSPITAL   (Lebanon)

^j AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^k CHU Oran   (Algeria)

^l AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^m National University of Medical Sciences   (Pakistan)

ⁿ Service d'Hematologie et Oncologie Pediatrique   (Morocco)

^o SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^p KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; LEVOFLOXACIN; METHOTREXATE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; URSODEOXYCHOLIC ACID; VALACICLOVIR; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL PRACTICE; DRUG CHOICE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFECTION PREVENTION; INFORMED CONSENT; LUNG EXAMINATION; PROTECTIVE EQUIPMENT; PSYCHOLOGIC ASSESSMENT; SCREENING TEST; VEIN OCCLUSION;

EID: 84884685213     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hemonc.2013.04.001     Document Type: Article

References (18)

1. Freifeld AG, Bow EJ, Sepkowitz KA. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer, update by the infectious diseases society of america. Clin Infect Dis 2010;52:e56-93.
2. Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant; 46:709-18.
3. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant 2009;44:453-5.
4. Lee SJ, Astigarraga CC, Eapen M, et al. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008;14:1231-8.
5. Pidala J, Lee SJ, Quinn G, Jim H, Kim J, Anasetti C. Variation in management of immune suppression after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant; 17:1528-36.
6. Ruutu T, Corradini P, Gratwohl A, et al. Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2005;35:121-4.
7. Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004;33:735-9.
8. Lee SJ, Joffe S, Artz AS, et al. Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol 2008;26:2162-70.
9. Lee SJ, Joffe S, Kim HT, et al. Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood 2004;104:2194-200.
10. Aljurf MD, Zaidi SZ, El Solh H, et al. Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report. Bone Marrow Transplant 2009;43:1-12.
11. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-9.
12. Grulke N, Larbig W, Kachele H, Bailer H. Pretransplant depression as risk factor for survival of patients undergoing allogeneic haematopoietic stem cell transplantation. Psychooncology 2008;17:480-7.
13. Loberiza Jr FR, Rizzo JD, Bredeson CN, et al. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol 2002;20:2118-26.
14. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
15. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:975-81.
16. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic venoocclusive disease after stem cell transplantation. Am J Hematol 2000;64:32-8.
17. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:206-17.
18. Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009;113:5711-9.